CAJ | 학술논문

目的：对比吸入型糖皮质激素联合辅舒良及顺尔宁与吸入型糖皮质激素联合辅舒良治疗哮喘合并中重度持续性过敏性鼻炎的临床疗效。方法：将2011年1月至2013年1月广州医科大学第一附属医院收治的55例哮喘合并中重度持续性过敏性鼻炎患者作为研究对象，对照组使用吸入型糖皮质激素联合辅舒良治疗(20例)，治疗组使用吸入型糖皮质激素联合辅舒良及顺尔宁联合治疗(35例)。治疗前及治疗后3个月，检测患者肺功能并进行病情症状及体征记分，并比较临床疗效。结果：观察组和对照组治疗后3个月肺功能指标第1秒用力呼气量占预计值百分比( FEV1％)、最大呼气中期流速占预计值百分比( MMEF％)与治疗前比较，差异均有统计学意义( P<0.05)。观察组治疗后MMEF％与对照组比较，差异有统计学意义( P<0.05)。治疗后3个月，患者过敏性鼻炎的喷嚏、流涕次数、鼻堵、鼻痒等症状均明显好转，其中观察组总有效率高于对照组( P<0.05)。结论：吸入型糖皮质激素联合辅舒良及顺尔宁能更有效控制患者支气管哮喘及中重度持续性过敏性鼻炎的临床症状，并显著提高肺功能。
목적：대비흡입형당피질격소연합보서량급순이저여흡입형당피질격소연합보서량치료효천합병중중도지속성과민성비염적림상료효。방법：장2011년1월지2013년1월엄주의과대학제일부속의원수치적55례효천합병중중도지속성과민성비염환자작위연구대상，대조조사용흡입형당피질격소연합보서량치료(20례)，치료조사용흡입형당피질격소연합보서량급순이저연합치료(35례)。치료전급치료후3개월，검측환자폐공능병진행병정증상급체정기분，병비교림상료효。결과：관찰조화대조조치료후3개월폐공능지표제1초용력호기량점예계치백분비( FEV1％)、최대호기중기류속점예계치백분비( MMEF％)여치료전비교，차이균유통계학의의( P<0.05)。관찰조치료후MMEF％여대조조비교，차이유통계학의의( P<0.05)。치료후3개월，환자과민성비염적분체、류체차수、비도、비양등증상균명현호전，기중관찰조총유효솔고우대조조( P<0.05)。결론：흡입형당피질격소연합보서량급순이저능경유효공제환자지기관효천급중중도지속성과민성비염적림상증상，병현저제고폐공능。
Objective:To assess the efficacy of inhaled corticosteroid combined with intranasal FlixonaseTM or oral SingulairTM in patients with asthma who had moderate to severe persistent allergic rhinitis. Methods:Between January 2011 and January 2013, we enrolled 55 patients with asthma who had moderate to severe persistent allergic rhinitis who were randomly allocated to be treated with inhaled corticosteroid plus intranasal FlixonaseTM alone ( control group, n=20) or in combination with oral SingulairTM ( observation group, n=35) for 3 consecutive months. Assessments of the symptom scores for asthma and rhinitis and lung function were conducted before and after treatment. Results: The between group differences in forced expiratory volume in 1 second per predicted ( FEV1%) and maximal mid expiratory flow per predicted ( MMEF%) were statistically significant ( both P<0. 05 ) before and after treatment. There were marked improvements in the symptoms of sneezing, runny nose, nasal congestion and nasal itching following 3 month therapy in both groups ( all P<0.05) . The observation group yielded a higher total effective rate than the control group ( P<0.05) . Conclusion:Inhaled corticosteroids combined with oral SingulairTM and intranasal FlixonaseTM significantly improve asthma control, alleviate symptoms and improve lung function in patients with asthma who have moderate to severe persistent allergic rhinitis.